
    
      This Phase 1, open-label, non-randomized, dose escalation, first-in-human study will assess
      the safety and tolerability of DS-1055a, determine the maximum tolerated dose of DS-1055a,
      pharmacokinetic (PK) properties of DS-1055a, and the incidence of anti-drug antibodies (ADAs)
      against DS-1055a and other antibodies.
    
  